(Q43299411)

18 November 2017

title

Mammalian target of rapamycin and autosomal dominant polycystic kidney disease (English)

1 reference

autosomal dominant polycystic kidney disease

18 November 2017

main subject

1 reference

1 reference

autosomal dominant polycystic kidney

1 reference

R P Wüthrich

1

1 reference

18 November 2017

A L Serra

series ordinal

2

1 reference

18 November 2017

language of work or name

English

0 references

publication date

10 July 2009

1 reference

Transplantation Proceedings

18 November 2017

published in

1 reference

18 November 2017

volume

41

1 reference

18 November 2017

issue

6 Suppl

1 reference

18 November 2017

page(s)

S18-20

1 reference

Clinical practice. Autosomal dominant polycystic kidney disease

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Molecular pathogenesis of ADPKD and development of targeted therapeutic options.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Autosomal dominant polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Vasopressin antagonists in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

mTOR is out of control in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Angiogenesis in autosomal-dominant polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Involvement of hypoxia-inducible transcription factors in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Rate of functional deterioration in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Volume progression in polycystic kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Sirolimus reduces polycystic liver volume in ADPKD patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.06.097

10.1016/J.TRANSPROCEED.2009.06.097

7 January 2021

Identifiers

DOI

1 reference

18 November 2017

1 reference